Metraipolis › archive › dc_c8bcf0629f79

Setanaxib Added to Pembrolizumab for Fibroblast-Rich, Recurrent, or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Phase II Randomized Study — Europe PMC PMID:42821626

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42821626
DOI
10.1158/2767-9764.crc-26-0422
License (as archived)
solo-consultazione
Archived
2026-11-01T03:33:31.852Z
SHA-256 of the archived text
89aef16e7df018ea96872ce170770c712f77b67c1b54730e53049b67c5609e26
Stable URL of this page
https://metraipolis.com/documento/dc_c8bcf0629f79

How to cite

Setanaxib Added to Pembrolizumab for Fibroblast-Rich, Recurrent, or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Phase II Randomized Study — Europe PMC PMID:42821626 — Europe PMC (en), https://europepmc.org/article/MED/42821626 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_c8bcf0629f79 (Metraipolis archive dc_c8bcf0629f79, sha256 89aef16e7df018ea96872ce170770c712f77b67c1b54730e53049b67c5609e26)
BibTeX
@misc{dcc8bcf0629f79,
  title = {Setanaxib Added to Pembrolizumab for Fibroblast-Rich, Recurrent, or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Phase II Randomized Study — Europe PMC PMID:42821626},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42821626},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_c8bcf0629f79; sha256 89aef16e7df018ea96872ce170770c712f77b67c1b54730e53049b67c5609e26},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42821626. Agents can read the archived copy with the MCP tool read_document.